Literature DB >> 31396918

Osteoglycin and Bone-a Systematic Review.

Jakob Starup-Linde1,2, Rikke Viggers3, Aase Handberg4,5.   

Abstract

PURPOSE OF REVIEW: Bone turnover is a regulated process. Osteoglycin is suggested to have an important impact on bone function but may also affect cardiovascular and metabolic functions. This review investigates the action of osteoglycin in bone as well as its potential endocrine effects. RECENT
FINDINGS: Osteoglycin is expressed by several tissues including bone and muscle. Some studies suggest that osteoglycin increases osteoblast differentiation whereas others suggest that osteoglycin decreases osteoblast differentiation. Thus, findings on the influence of osteoglycin in bone are conflicting. A recent study found increased bone mass in osteoglycin deficient mice. Another study reported that osteoglycin is a marker of low bone mineral density and vertebral fractures in women with type 2 diabetes. Furthermore, clinical studies link osteoglycin to insulin resistance and cardiovascular disease. Osteoglycin may be a novel marker of a muscle, pancreatic, and bone axis. However, current evidence is limited and further research investigating osteoglycin in both a pre-clinical and a clinical setting is needed.

Entities:  

Keywords:  Bone; Bone turnover; Insulin resistance; Osteoglycin

Mesh:

Substances:

Year:  2019        PMID: 31396918     DOI: 10.1007/s11914-019-00523-z

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN: 1544-1873            Impact factor:   5.096


  47 in total

Review 1.  Osteoclast differentiation and activation.

Authors:  William J Boyle; W Scott Simonet; David L Lacey
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

Review 2.  Biochemical bone turnover markers in diabetes mellitus - A systematic review.

Authors:  Jakob Starup-Linde; Peter Vestergaard
Journal:  Bone       Date:  2015-02-24       Impact factor: 4.398

3.  Molecular cloning of a novel bone-forming compound: osteoinductive factor.

Authors:  L Madisen; M Neubauer; G Plowman; D Rosen; P Segarini; J Dasch; A Thompson; J Ziman; H Bentz; A F Purchio
Journal:  DNA Cell Biol       Date:  1990-06       Impact factor: 3.311

4.  Higher Serum Levels of Osteoglycin Are Associated with All-Cause Mortality and Cardiovascular and Cerebrovascular Events in Patients with Advanced Chronic Kidney Disease.

Authors:  Seon Ha Baek; Ran-Hui Cha; Shin Wook Kang; Cheol Whee Park; Dae Ryong Cha; Sung Gyun Kim; Sun Ae Yoon; Sejoong Kim; Sang Youb Han; Jung Hwan Park; Jae Hyun Chang; Chun Soo Lim; Yon Su Kim; Ki Young Na
Journal:  Tohoku J Exp Med       Date:  2017-08       Impact factor: 1.848

5.  Differential impact of glucose administered intravenously or orally on bone turnover markers in healthy male subjects.

Authors:  Sidse Westberg-Rasmussen; Jakob Starup-Linde; Kjeld Hermansen; Jens Juul Holst; Bolette Hartmann; Peter Vestergaard; Søren Gregersen
Journal:  Bone       Date:  2017-01-23       Impact factor: 4.398

6.  Bone morphogenetic protein-1/tolloid-related metalloproteinases process osteoglycin and enhance its ability to regulate collagen fibrillogenesis.

Authors:  Gaoxiang Ge; Neung-Seon Seo; Xiaowen Liang; Delana R Hopkins; Magnus Höök; Daniel S Greenspan
Journal:  J Biol Chem       Date:  2004-07-29       Impact factor: 5.157

7.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.

Authors:  Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher
Journal:  BMJ       Date:  2009-07-21

Review 8.  What do we know about biochemical bone markers?

Authors:  P D Delmas
Journal:  Baillieres Clin Obstet Gynaecol       Date:  1991-12

Review 9.  Gone with the Wnts: beta-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism.

Authors:  Stavros C Manolagas; Maria Almeida
Journal:  Mol Endocrinol       Date:  2007-07-10

10.  Integrated genomic approaches implicate osteoglycin (Ogn) in the regulation of left ventricular mass.

Authors:  Enrico Petretto; Rizwan Sarwar; Ian Grieve; Han Lu; Mande K Kumaran; Phillip J Muckett; Jonathan Mangion; Blanche Schroen; Matthew Benson; Prakash P Punjabi; Sanjay K Prasad; Dudley J Pennell; Chris Kiesewetter; Elena S Tasheva; Lolita M Corpuz; Megan D Webb; Gary W Conrad; Theodore W Kurtz; Vladimir Kren; Judith Fischer; Norbert Hubner; Yigal M Pinto; Michal Pravenec; Timothy J Aitman; Stuart A Cook
Journal:  Nat Genet       Date:  2008-05       Impact factor: 38.330

View more
  4 in total

Review 1.  In Vitro Cytological Responses against Laser Photobiomodulation for Periodontal Regeneration.

Authors:  Yujin Ohsugi; Hiromi Niimi; Tsuyoshi Shimohira; Masahiro Hatasa; Sayaka Katagiri; Akira Aoki; Takanori Iwata
Journal:  Int J Mol Sci       Date:  2020-11-26       Impact factor: 5.923

2.  A Novel Ex Vivo Approach Based on Proteomics and Biomarkers to Evaluate the Effects of Chrysene, MEHP, and PBDE-47 on Loggerhead Sea Turtles (Caretta caretta).

Authors:  Laura Bianchi; Silvia Casini; Lorenza Vantaggiato; Agata Di Noi; Alfonso Carleo; Enxhi Shaba; Alessandro Armini; Francesco Bellucci; Giovanni Furii; Luca Bini; Ilaria Caliani
Journal:  Int J Environ Res Public Health       Date:  2022-04-05       Impact factor: 3.390

3.  Osteoglycin as a Potential Biomarker of Mild Kidney Function Impairment in Type 2 Diabetes Patients.

Authors:  Sheila González-Salvatierra; Cristina García-Fontana; Francisco Andújar-Vera; Alejandro Borja Grau-Perales; Luis Martínez-Heredia; María Dolores Avilés-Pérez; María Hayón-Ponce; Iván Iglesias-Baena; Blanca Riquelme-Gallego; Manuel Muñoz-Torres; Beatriz García-Fontana
Journal:  J Clin Med       Date:  2021-05-20       Impact factor: 4.241

4.  Associations of Circulating Osteoglycin With Bone Parameters and Metabolic Markers in Patients With Diabetes.

Authors:  Jakob Kau Starup-Linde; Rikke Viggers; Bente Langdahl; Soeren Gregersen; Simon Lykkeboe; Aase Handberg; Peter Vestergaard
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-15       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.